DRUGS MADE IN AMERICA AC-RTS (DMAAR) Fundamental Analysis & Valuation

NASDAQ:DMAAR

Current stock price

0.049 USD
+0.01 (+12.64%)
Last:

This DMAAR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. DMAAR Profitability Analysis

1.1 Basic Checks

  • DMAAR had positive earnings in the past year.
DMAAR Yearly Net Income VS EBIT VS OCF VS FCFDMAAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -50K -100K -150K -200K -250K

1.2 Ratios

Industry RankSector Rank
ROA 2.29%
ROE 2.37%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DMAAR Yearly ROA, ROE, ROICDMAAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 0 50 -50 100

1.3 Margins

  • DMAAR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMAAR Yearly Profit, Operating, Gross MarginsDMAAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. DMAAR Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for DMAAR has been reduced compared to 1 year ago.
DMAAR Yearly Shares OutstandingDMAAR Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 20M 40M 60M
DMAAR Yearly Total Debt VS Total AssetsDMAAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 200K 400K 600K

2.2 Solvency

  • DMAAR has an Altman-Z score of 0.06. This is a bad value and indicates that DMAAR is not financially healthy and even has some risk of bankruptcy.
  • There is no outstanding debt for DMAAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.06
ROIC/WACCN/A
WACCN/A
DMAAR Yearly LT Debt VS Equity VS FCFDMAAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 -50K -100K -150K -200K

2.3 Liquidity

  • A Current Ratio of 0.06 indicates that DMAAR may have some problems paying its short term obligations.
  • A Quick Ratio of 0.06 indicates that DMAAR may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
DMAAR Yearly Current Assets VS Current LiabilitesDMAAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2024 200K 400K 600K

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. DMAAR Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

2

4. DMAAR Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 0.24, the valuation of DMAAR can be described as very cheap.
  • When comparing the Price/Earnings ratio of DMAAR to the average of the S&P500 Index (25.61), we can say DMAAR is valued rather cheaply.
Industry RankSector Rank
PE 0.25
Fwd PE N/A
DMAAR Price Earnings VS Forward Price EarningsDMAAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMAAR Per share dataDMAAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DMAAR Dividend Analysis

5.1 Amount

  • No dividends for DMAAR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DMAAR Fundamentals: All Metrics, Ratios and Statistics

DRUGS MADE IN AMERICA AC-RTS

NASDAQ:DMAAR (3/26/2026, 2:23:06 PM)

0.049

+0.01 (+12.64%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)03-18
Earnings (Next)05-06
Inst Owners70.25%
Inst Owner Change0.08%
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap1.64M
Revenue(TTM)N/A
Net Income(TTM)5.45M
AnalystsN/A
Price TargetN/A
Short Float %0.03%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.25
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.01
P/tB 0.01
EV/EBITDA N/A
EPS(TTM)0.2
EY408.16%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS6.87
TBVpS6.87
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.56
Profitability
Industry RankSector Rank
ROA 2.29%
ROE 2.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z 0.06
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

DRUGS MADE IN AMERICA AC-RTS / DMAAR Fundamental Analysis FAQ

What is the fundamental rating for DMAAR stock?

ChartMill assigns a fundamental rating of 1 / 10 to DMAAR.


What is the valuation status for DMAAR stock?

ChartMill assigns a valuation rating of 2 / 10 to DRUGS MADE IN AMERICA AC-RTS (DMAAR). This can be considered as Overvalued.


Can you provide the profitability details for DRUGS MADE IN AMERICA AC-RTS?

DRUGS MADE IN AMERICA AC-RTS (DMAAR) has a profitability rating of 0 / 10.


What is the financial health of DRUGS MADE IN AMERICA AC-RTS (DMAAR) stock?

The financial health rating of DRUGS MADE IN AMERICA AC-RTS (DMAAR) is 4 / 10.